DUBLIN, March 18, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam),…Original Article
Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
